ZIVO Bioscience (ZIVO) Stock Analysis & Winston Score
ZIVO Bioscience is a small biotech company that develops natural compounds from algae. Its main focus is on a microalgae strain called Chlorella, which it believes contains bioactive ingredients that could support immune health. The company is working on products for two main markets: animal health (like poultry and livestock feed additives) and human health supplements. ZIVO earns revenue through licensing agreements, where it partners with larger companies that pay to use its algae-derived ingredients in their own products. It is a very small, early-stage company based in the United States with a market cap near zero, meaning it has not yet built a large commercial business. The massive negative operating margin reflects heavy spending on research with little revenue coming in, and the key risk is that the company may need to raise more cash to survive while it waits for its products to gain regulatory approval and commercial traction.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Data not available (0/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $4.14
Market Cap: $16M
Sector: Healthcare
Industry: Biotechnology

